Rosacea – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Rosacea – Pipeline Review, H1 2020’, provides an overview of the Rosacea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Rosacea

– The report reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Rosacea therapeutics and enlists all their major and minor projects

– The report assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Rosacea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rosacea

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accuitis Pharmaceuticals Inc

Afecta Pharmaceuticals Inc

Aiviva BioPharma Inc

AlfaSigma SpA

AOBiome LLC

Biomimetix JV LLC

BioPharmX Inc

Botanix Pharmaceuticals Ltd

Cellix Bio Pvt Ltd

Cutanea Life Sciences Inc

Dermata Therapeutics LLC

ELORAC Inc

Emeriti Pharma AB

GlycoMira Therapeutics Inc

Hovione FarmaCiencia SA

Maruho Co Ltd

Matrisys Bioscience Inc

Menlo Therapeutics Inc

Sol-Gel Technologies Ltd

Sunny Pharmtech Inc

Tarsus Pharmaceuticals Inc

TWi Biotechnology Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rosacea - Overview

Rosacea - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Rosacea - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rosacea - Companies Involved in Therapeutics Development

Accuitis Pharmaceuticals Inc

Afecta Pharmaceuticals Inc

Aiviva BioPharma Inc

AlfaSigma SpA

AOBiome LLC

Biomimetix JV LLC

BioPharmX Inc

Botanix Pharmaceuticals Ltd

Cellix Bio Pvt Ltd

Cutanea Life Sciences Inc

Dermata Therapeutics LLC

ELORAC Inc

Emeriti Pharma AB

GlycoMira Therapeutics Inc

Hovione FarmaCiencia SA

Maruho Co Ltd

Matrisys Bioscience Inc

Menlo Therapeutics Inc

Sol-Gel Technologies Ltd

Sunny Pharmtech Inc

Tarsus Pharmaceuticals Inc

TWi Biotechnology Inc

Rosacea - Drug Profiles

AC-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACUD-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AFX-4031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AIV-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzoyl peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMX-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTX-1702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbamide peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-1621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXDER-621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXDER-622 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXDER-623 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxycycline hyclate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-0003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FMX-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HY-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-1220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifaximin DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rosacea - Dormant Projects

Rosacea - Discontinued Products

Rosacea - Product Development Milestones

Featured News & Press Releases

Feb 18, 2020: Foamix announces integrated efficacy results from the FMX103

1.5% Topical Minocycline Foam Phase 3 program for Rosacea

Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks

Feb 06, 2020: Foamix announces publication of Phase 3 Studies evaluating FMX103 for the treatment of papulopustular rosacea in Journal of the American Academy of Dermatology

Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting

Dec 09, 2019: Botanix initiates BTX 1702 rosacea study

Oct 23, 2019: Foamix enters into manufacturing and supply agreement For FMX103

Oct 17, 2019: Foamix announces FDA acceptance of its New Drug Application for FMX103 Minocycline foam for the treatment of Moderate-to-Severe Papulopustular Rosacea

Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

Oct 10, 2019: Foamix to present data on FMX-103 at 39th Annual Fall Clinical Dermatology Conference

Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel

Aug 06, 2019: Foamix seeks FDA approval for FMX103 to treat rosacea

Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea

Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea

May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea

Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Rosacea, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Rosacea – Pipeline by Accuitis Pharmaceuticals Inc, H1 2020

Rosacea – Pipeline by Afecta Pharmaceuticals Inc, H1 2020

Rosacea – Pipeline by Aiviva BioPharma Inc, H1 2020

Rosacea – Pipeline by AlfaSigma SpA, H1 2020

Rosacea – Pipeline by AOBiome LLC, H1 2020

Rosacea – Pipeline by Biomimetix JV LLC, H1 2020

Rosacea – Pipeline by BioPharmX Inc, H1 2020

Rosacea – Pipeline by Botanix Pharmaceuticals Ltd, H1 2020

Rosacea – Pipeline by Cellix Bio Pvt Ltd, H1 2020

Rosacea – Pipeline by Cutanea Life Sciences Inc, H1 2020

Rosacea – Pipeline by Dermata Therapeutics LLC, H1 2020

Rosacea – Pipeline by ELORAC Inc, H1 2020

Rosacea – Pipeline by Emeriti Pharma AB, H1 2020

Rosacea – Pipeline by GlycoMira Therapeutics Inc, H1 2020

Rosacea – Pipeline by Hovione FarmaCiencia SA, H1 2020

Rosacea – Pipeline by Maruho Co Ltd, H1 2020

Rosacea – Pipeline by Matrisys Bioscience Inc, H1 2020

Rosacea – Pipeline by Menlo Therapeutics Inc, H1 2020

Rosacea – Pipeline by Sol-Gel Technologies Ltd, H1 2020

Rosacea – Pipeline by Sunny Pharmtech Inc, H1 2020

Rosacea – Pipeline by Tarsus Pharmaceuticals Inc, H1 2020

Rosacea – Pipeline by TWi Biotechnology Inc, H1 2020

Rosacea – Dormant Projects, H1 2020

Rosacea – Dormant Projects, H1 2020 (Contd..1), H1 2020

Rosacea – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Rosacea, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports